Adial Pharmaceuticals

ADILPhase 3

Glen Allen, United StatesFounded 2010adial.com

Adial Pharmaceuticals is focused on the treatment and prevention of addictions and related disorders through a science-driven, genetically targeted approach. Its lead investigational drug, AD04, is a serotonin-3 receptor antagonist being developed for Alcohol Use Disorder in patients with specific genotypes, supported by a proprietary companion diagnostic. The company, founded in 2010 and listed on NASDAQ in 2018, is navigating late-stage clinical development and has recently signed a significant collaboration framework for Europe. Adial's mission is to build a leading pharmaceutical company improving the quality of life for patients suffering from addiction.

Market Cap

$2.9M

Founded

2010

Focus

Small Molecules

ADIL · Stock Price

USD 2.001273.00 (-99.84%)

Historical price data

AI Company Overview

Technology Platform

A genetically targeted pharmacotherapy platform for addiction, centered on a serotonin-3 receptor antagonist (AD04) paired with a proprietary companion diagnostic genetic test to identify patient subpopulations most likely to respond.

Pipeline Snapshot

1 drug in pipeline, 1 in Phase 3

Drug	Indication	Stage
AD04 (ondansetron) + Matching placebo	Alcohol Use Disorder	Phase 3

Opportunities

The primary opportunity is addressing the vast unmet need in Alcohol Use Disorder with a first-in-class, genetically targeted therapy.

Success could establish a new precision medicine paradigm in addiction treatment.

Further opportunities include geographic expansion through partnerships (as initiated in Europe) and potential pipeline expansion into other substance use disorders leveraging the core genetic targeting platform.

Risk Factors

Key risks include clinical/regulatory uncertainty following mixed Phase 3 results, the need for potentially significant additional financing, the challenge of commercializing a novel drug-diagnostic combination, and reliance on a single lead asset.

Execution of the European partnership and clear FDA guidance are critical near-term hurdles.

Competitive Landscape

Adial competes against generic AUD medications (naltrexone, acamprosate, disulfiram) and behavioral therapies. Its main differentiation is the genetically targeted, companion diagnostic-driven approach, which is unique in the AUD space. Pipeline competitors are exploring diverse mechanisms, but few are pursuing a similar precision medicine strategy, potentially giving AD04 a distinct niche if clinically validated.